Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium sa-nv - clostridium haemolyticum toxoid >= 16,5 u/ml; tetanus toxoid >= 2,5 u/ml; clostridium septicum toxoid >= 3,6 u/ml; clostridium novyi toxoid >= 1,2 u/ml; clostridium perfringens type c (beta) toxoid >= 12,4 u/ml; clostridium perfringens type d (epsilon) toxoid >= 5,1 u/ml; clostridium perfringens type a toxoid >= 0,9 u/ml; clostridium perfringens type b toxoid >= 12,4 u/ml; clostridium chauvoei (inactivated) ; clostridium sordellii toxoïd >= 0,8 u/ml - suspension for injection - clostridium chauvoei-septicum; clostridium haemolyticum toxoid; clostridium novyi toxoid; clostridium perfringens; clostridium tetani toxoid; clostridium sordellii toxoid - clostridium - cattle; sheep

Nový Zéland - angličtina - Ministry for Primary Industries

schering-plough animal health limited - clostridium septicum (strain 3204) toxoid; clostridium perfringens type d toxoid; clostridium septicum (strain 368) toxoid; hydroxocobalamin acetate; clostridium novyi type b toxoid/cells; sodium selenate; clostridium chauvoei whole culture; clostridium tetani toxoid - clostridium septicum (strain 3204) toxoid 0 vaccine; clostridium perfringens type d toxoid 0 vaccine; clostridium septicum (strain 368) toxoid 0 vaccine; hydroxocobalamin acetate 1 g/litre; clostridium novyi type b toxoid/cells 0 vaccine; sodium selenate 2.4 g/litre; clostridium chauvoei whole culture 0 vaccine; clostridium tetani toxoid 0 vaccine - vaccine

Velká Británie - angličtina - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - clostridium perfringens, clostridium tetani - suspension for injection - inactivated bacterial vaccine - pigs, sheep

Velká Británie - angličtina - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - clostridium chauvoei, clostridium perfringens, clostridium septicum, clostridium tetani, mannheimia haemolytica, pasteurella trehalosi - solution for injection - inactivated bacterial vaccine - sheep

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - clostridium perfringens type d (epsilon) toxoid ; clostridium perfringens type c (beta) toxoid >= 18,2 iu/dose; clostridium perfringens type b toxoid >= 18,2 iu/dose; clostridium sordellii toxoïd >= 4,4 u/ml; clostridium perfringens type a (alfa) toxoid >= 0,5 u/ml; clostridium novyi toxoid >= 3,8 iu/ml; clostridium septicum toxoid >= 4,6 elisa u/dose; clostridium chauvoei (inactivated) ; clostridium haemolyticum toxoid >= 17,4 u/ml; tetanus toxoid >= 4,9 elisa u/dose - suspension for injection - clostridium haemolyticum toxoid; clostridium tetani toxoid; clostridium novyi toxoid; clostridium chauvoei; clostridium perfringens; clostridium sordellii toxoid - clostridium - cattle; sheep

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

idt biologika gmbh - clostridium perfringens type a/c, beta2 toxoid ; clostridium perfringens type a/c, alfa toxoid ; clostridium perfringens type a/c, beta1 toxoid - lyophilisate and solvent for suspension for injection - clostridium perfringens type a/c, alfa toxoid; clostridium perfringens type a/c, beta1 toxoid; clostridium perfringens type a/c, beta2 toxoid - clostridium - pig

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

idt biologika gmbh - clostridium perfringens type a/c, beta2 toxoid ; clostridium perfringens type a/c, alfa toxoid ; clostridium perfringens type a/c, beta1 toxoid - lyophilisate and solvent for suspension for injection - clostridium perfringens type a/c, alfa toxoid; clostridium perfringens type a/c, beta1 toxoid; clostridium perfringens type a/c, beta2 toxoid - clostridium - pig

Nový Zéland - angličtina - Ministry for Primary Industries

zoetis new zealand limited - clostridium chauvoei toxoid/cells; clostridium novyi type b toxoid/cells; selenium; corynebacterium pseudotuberculosis exotoxin; hydroxocobalamin; moxidectin; clostridium tetani toxoid; clostridium perfringens type d toxoid; clostridium septicum toxoid - clostridium chauvoei toxoid/cells 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; selenium 1 g/litre; corynebacterium pseudotuberculosis exotoxin 0 vaccine; hydroxocobalamin 1 g/litre; moxidectin 5 g/litre; clostridium tetani toxoid 0 vaccine; clostridium perfringens type d toxoid 0 vaccine; clostridium septicum toxoid 0 vaccine - parenteral nutrient/electrolyte

Spojené státy - angličtina - NLM (National Library of Medicine)

sanofi pasteur inc. - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h) - clostridium tetani toxoid antigen (formaldehyde inactivated) 5 [lf] in 0.5 ml - tenivac® is a vaccine indicated for active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of tenivac or any other tetanus toxoid or diphtheria toxoid-containing vaccine or any other component of this vaccine is a contraindication to administration of tenivac. [see description (11) .] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no adequate and well-controlled studies of tenivac administration in pregnant women in t

Spojené státy - angličtina - NLM (National Library of Medicine)

sanofi pasteur inc. - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - clostridium tetani toxoid antigen (formaldehyde inactivated) 5 [lf] in 0.5 ml - adacel® is a vaccine indicated for: - active booster immunization against tetanus, diphtheria and pertussis. adacel is approved for use in individuals 10 through 64 years of age. immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid, diphtheria toxoid or pertussis containing vaccine or any other component of this vaccine is a contraindication to administration of adacel. [see description (11). ] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. encephalopathy (e.g., coma, prolonged seizures, or decreased level of consciousness) within 7 days of a previous dose of a pertussis containing vaccine not attributable to another identifiable cause is a contraindicatio